Predictors of Enrollment of Older Smokers in Six Smoking Cessation Trials in the Lung Cancer Screening Setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
05 11 2021
Historique:
received: 04 11 2020
accepted: 01 06 2021
pubmed: 3 6 2021
medline: 6 1 2022
entrez: 2 6 2021
Statut: ppublish

Résumé

Increased rates of smoking cessation will be essential to maximize the population benefit of low-dose CT screening for lung cancer. The NCI's Smoking Cessation at Lung Examination (SCALE) Collaboration includes eight randomized trials, each assessing evidence-based interventions among smokers undergoing lung cancer screening (LCS). We examined predictors of trial enrollment to improve future outreach efforts for cessation interventions offered to older smokers in this and other clinical settings. We included the six SCALE trials that randomized individual participants. We assessed demographics, intervention modalities, LCS site and trial administration characteristics, and reasons for declining. Of 6285 trial- and LCS-eligible individuals, 3897 (62%) declined and 2388 (38%) enrolled. In multivariable logistic regression analyses, Blacks had higher enrollment rates (OR 1.5, 95% CI 1.2,1.8) compared to Whites. Compared to "NRT Only" trials, those approached for "NRT + prescription medication" trials had higher odds of enrollment (OR 6.1, 95% CI 4.7,7.9). Regarding enrollment methods, trials using "Phone + In Person" methods had higher odds of enrollment (OR 1.6, 95% CI 1.2,1.9) compared to trials using "Phone Only" methods. Some of the reasons for declining enrollment included "too busy" (36.6%), "not ready to quit" (8.2%), "not interested in research" (7.7%), and "not interested in the intervention offered" (6.2%). Enrolling smokers in cessation interventions in the LCS setting is a major priority that requires multiple enrollment and intervention modalities. Barriers to enrollment provide insights that can be addressed and applied to future cessation interventions to improve implementation in LCS and other clinical settings with older smokers. We explored enrollment rates and reasons for declining across six smoking cessation trials in the lung cancer screening setting. Offering multiple accrual methods and pharmacotherapy options predicted increased enrollment across trials. Enrollment rates were also greater among Blacks compared to Whites. The findings offer practical information for the implementation of cessation trials and interventions in the lung cancer screening context and other clinical settings, regarding intervention modalities that may be most appealing to older, long-term smokers.

Identifiants

pubmed: 34077535
pii: 6291028
doi: 10.1093/ntr/ntab110
pmc: PMC8570664
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2037-2046

Subventions

Organisme : NCI NIH HHS
ID : R01 CA218123
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207229
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA214839
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207228
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009461
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207158
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207078
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196873
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207442
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Références

Contemp Clin Trials. 2020 Apr;91:105963
pubmed: 32087340
Am J Prev Med. 2019 Aug;57(2):250-255
pubmed: 31248742
Lung Cancer. 2012 May;76(2):204-10
pubmed: 22054915
Health Psychol. 2011 Jan;30(1):40-8
pubmed: 21299293
PLoS One. 2013 Aug 07;8(8):e71379
pubmed: 23940744
Epidemiology. 1993 Jul;4(4):295-302
pubmed: 8347739
Nicotine Tob Res. 2016 Jul;18(7):1665-9
pubmed: 26834052
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Oncologist. 2016 Jan;21(1):40-9
pubmed: 26712960
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):617-9
pubmed: 17337647
Lung Cancer. 2017 Jun;108:242-246
pubmed: 28216065
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Contemp Clin Trials. 2017 Sep;60:86-95
pubmed: 28687349
Lung Cancer. 2007 Apr;56(1):125-34
pubmed: 17196298
Open Med (Wars). 2016 Dec 30;11(1):605-610
pubmed: 28352853
Cochrane Database Syst Rev. 2017 Sep 12;9:CD004305
pubmed: 28898403
Lung Cancer. 2016 Aug;98:91-98
pubmed: 27393513
Lung Cancer. 2019 Sep;135:205-216
pubmed: 31446996
Nicotine Tob Res. 2013 Dec;15(12):2107-13
pubmed: 23911847
Cancer. 2013 Apr 1;119(7):1381-5
pubmed: 23440730
Prev Med. 2014 May;62:38-43
pubmed: 24508983
J Natl Med Assoc. 2009 May;101(5):450-5
pubmed: 19476198
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):12-8
pubmed: 16434580
Nicotine Tob Res. 2010 Oct;12(10):989-96
pubmed: 20713440
Lung Cancer. 2004 Apr;44(1):13-21
pubmed: 15013579
J Public Health Manag Pract. 2006 Jan-Feb;12(1):37-43
pubmed: 16340514
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
J Thorac Oncol. 2020 Jul;15(7):1160-1169
pubmed: 32160967
J Consult Clin Psychol. 2004 Jun;72(3):371-81
pubmed: 15279521
Nicotine Tob Res. 2006 Dec;8 Suppl 1:S43-8
pubmed: 17491170
Ann Behav Med. 2005 Jun;29(3):181-91
pubmed: 15946112
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009187
pubmed: 23235672
Prev Chronic Dis. 2014 Jul 31;11:E131
pubmed: 25078568
PLoS One. 2014 Dec 01;9(12):e93456
pubmed: 25437212
Am J Prev Med. 2008 May;34(5):404-12
pubmed: 18407007
Lung Cancer. 2012 May;76(2):211-5
pubmed: 22088938
Tob Control. 2007 Dec;16 Suppl 1:i42-6
pubmed: 18048631
J Thorac Oncol. 2019 Sep;14(9):1528-1537
pubmed: 31077790
Contemp Clin Trials. 2019 Jul;82:25-35
pubmed: 31129371
Am J Respir Crit Care Med. 2018 Jan 15;197(2):172-182
pubmed: 28977754
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441
pubmed: 29632061
Am J Health Behav. 2012 Sep;36(5):577-88
pubmed: 22584086
Health Commun. 2011 Dec;26(8):735-42
pubmed: 21667366
Ann Epidemiol. 2002 Apr;12(3):206-12
pubmed: 11897179

Auteurs

Ellie Eyestone (E)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Randi M Williams (RM)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

George Luta (G)

Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.

Emily Kim (E)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Benjamin A Toll (BA)

Department of Public Health Sciences and Psychiatry, Medical University of South Carolina, Charleston, SC, USA.

Alana Rojewski (A)

Department of Public Health Sciences and Psychiatry, Medical University of South Carolina, Charleston, SC, USA.

Jordan Neil (J)

Department of Medicine, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA.

Paul M Cinciripini (PM)

Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Marisa Cordon (M)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Kristie Foley (K)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Jennifer S Haas (JS)

Department of Medicine, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA.

Anne M Joseph (AM)

Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Jennifer A Minnix (JA)

Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jamie S Ostroff (JS)

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Elyse Park (E)

Department of Psychiatry, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA.

Nancy Rigotti (N)

Department of Medicine, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA.

Lia Sorgen (L)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Kathryn L Taylor (KL)

Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH